Explore the words cloud of the MACIVIVA project. It provides you a very rough idea of what is the project "MACIVIVA" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||8˙438˙905 €|
|EC max contribution||5˙338˙886 € (63%)|
1. H2020-EU.220.127.116.11. (Developing next generation nanomaterials, nanodevices and nanosystems)
|Duration (year-month-day)||from 2015-05-04 to 2018-11-03|
Take a look of project's partnership.
|1||MYMETICS BV||NL (LEIDEN)||coordinator||1˙755˙073.00|
|2||UPPERTON LIMITED||UK (NOTTINGHAM)||participant||1˙647˙777.00|
|3||CATALENT U.K. SWINDON ZYDIS LIMITED||UK (SWINDON)||participant||1˙061˙723.00|
|4||CHIMERA BIOTEC GMBH||DE (DORTMUND)||participant||874˙312.00|
|5||BACHEM AG||CH (BUBENDORF)||participant||0.00|
|6||MYMETICS SA||CH (EPALINGES)||participant||0.00|
MACIVIVA is a highly interdisciplinary consortium among well established and innovative SMEs with scientific excellence and complementary industrial world-leading experts with unique expertise and know-how in virosome technology, spray and freeze drying, large scale manufacturing and packaging. MACIVIVA will pave the path to other large scale thermostable nanopharmaceuticals products for therapeutic and prophylactic vaccines and other potential applications for direct application by non-invasive routes. Liquid products are inherently prone to physical and/or chemical modifications and degradations. Solid vaccine dosage formats (e.g. powder) may prevent molecular motion and shear-induced degradation, and slow down degradation involving water and oxygen radicals, resulting in improved stability and enhanced shelf-life of vaccines. The cold chain storage is still fundamental for preserving the bioactivity of most liquid and freeze-dried vaccines, and a reconstitution step prior to administration is required for freeze dried vaccines that are usually administered intramuscularly or subcutaneously. These reconstituted freeze dried vaccines harbor important instability and must be used within hours and kept refrigerated. Because most liquid and reconstituted freeze-dried vaccines are susceptible to degradations, it may affect the immunological properties of the immunogens, with unwanted immune responses or insufficient immune protection. For addressing liquid virosome-based vaccine instability and improving their shelf-life outside the cold chain, MACIVIVA will explore new galenic vaccine formulations through careful screening of excipients, stabilization and drying methods for generating new vaccine solid forms that can be easily self-administered. Robust “universal” manufacturing processes for upscale production of virosome dried powder for the non-invasive intranasal, oral and sublingual routes should be achieved by month 42.
|MACIVIVA webpage launching||Websites, patent fillings, videos etc.||2019-05-30 11:28:43|
|MACIVIVA communication fact sheet||Other||2019-05-30 11:28:50|
|MACIVIVA logo||Other||2019-05-30 11:28:49|
Take a look to the deliverables list in detail: detailed list of MACIVIVA deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MACIVIVA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MACIVIVA" are provided by the European Opendata Portal: CORDIS opendata.
EURONANOFORUM 2019 - NANOTECHNOLOGY AND ADVANCED MATERIALS PROGRESS UNDER HORIZON2020 AND BEYONDRead More
Bringing innovAtion by Scaling up nanoMATerials and Inks for printingRead More
A Pilot Plant for the Production of Polymer based Nanopharmaceuticals in Compliance with GMPRead More